Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies

Transplantation

Volumn 95, Issue 1, 2013, Pages 177-183

  Waki, Kayo ^a   Sugawara, Yasuhiko ^a   Mizuta, Koichi ^b   Taniguchi, Michiko ^c   Ozawa, Miyuki ^c   Hirata, Masaru ^d   Nozawa, Masumi ^e   Kaneko, Junichi ^a   Takahashi, Koki ^f   Kadowaki, Takashi ^a   Terasaki, Paul I ^g   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c One Lambda Inc   (United States)

^d JR Tokyo General Hospital   (Japan)

^e MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^f UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^g TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

Human leukocyte antigen antibodies; Living donor liver transplantation; Operational tolerance; Pediatric

Indexed keywords

CYCLOSPORIN; HLA ANTIBODY; HLA B ANTIBODY; HLA C ANTIBODY; HLA CLASS I ANTIBODY; HLA CLASS II ANTIBODY; HLA DQ ANTIBODY; HLA DR ANTIBODY; METHYLPREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGICAL TOLERANCE; LIVER BIOPSY; LIVER TRANSPLANTATION; LIVING DONOR; MALE; OPERATIONAL TOLERANCE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; SEROLOGY; UNSPECIFIED SIDE EFFECT;

ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; INFANT; ISOANTIBODIES; LIVER TRANSPLANTATION; LIVING DONORS; MALE; RETROSPECTIVE STUDIES;

EID: 84872078847     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182782fef     Document Type: Article

References (54)

1. Traum AZ, Kawai T, Vacanti JP, et al. The need for tolerance in pediatric organ transplantation. Pediatrics 2008; 121: 1258.
2. Bishop GA, Ierino FL, Sharland AF, et al. Approaching the promise of operational tolerance in clinical transplantation. Transplantation 2011; 91: 1065.
3. Cuturi MC, Josien R, Douillard P, et al. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a. a. 75Y84) from the alpha 1 helix of the first domain of HLA-B7 01. Transplantation 1995; 59: 661.
4. Gianello P, Fishbein JM, Sachs DH. Tolerance to primarily vascularized allografts in miniature swine. Immunol Rev 1993; 133: 19.
5. Knechtle SJ. Knowledge about transplantation tolerance gained in primates. Curr Opin Immunol 2000; 12: 552.
6. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997; 159: 5187.
7. Remuzzi G, Rossini M, Imberti O, et al. Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. Lancet 1991; 337: 750.
8. Sablinski T, Hancock WW, Tilney NL, et al. CD4 monoclonal antibodies in organ transplantationVa review of progress. Transplantation 1991; 52: 579.
9. Subbotin V, Sun H, Aitouche A, et al. Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance. Transplantation 1997; 64: 690.
10. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009; 50: 1247.
11. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243.
12. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric livingdonor liver transplantation. Transpl Immunol 2007; 17: 94.
13. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307: 283.
14. Demetris AJ, Lunz JG 3rd, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22: 120.
15. Sriwatanawongsa V, Davies HS, Calne RY. The essential roles of parenchymal tissues and passenger leukocytes in the tolerance induced by liver grafting in rats. Nat Med 1995; 1: 428.
16. Sun J, McCaughan GW, Gallagher ND, et al. Deletion of spontaneous rat liver allograft acceptance by donor irradiation. Transplantation 1995; 60: 233.
17. Sun J, Sheil AG, Wang C, et al. Tolerance to rat liver allografts: IV. Acceptance depends on the quantity of donor tissue and on donor leukocytes. Transplantation 1996; 62: 1725.
18. Bowen DG, Zen M, Holz L, et al. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004; 114: 701.
19. Kamada N, Shinomiya T. Clonal deletion as the mechanism of abrogation of immunological memory following liver grafting in rats. Immunology 1985; 55: 85.
20. Qian S, Lu L, Fu F, et al. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol 1997; 158: 4654.
21. Sharland A, Shastry S, Wang C, et al. Kinetics of intragraft cytokine expression, cellular infiltration, and cell death in rejection of renal allografts compared with acceptance of liver allografts in a rat model: early activation and apoptosis is associated with liver graft acceptance. Transplantation 1998; 65: 1370.
22. Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated Tregulatory cells in liver transplant tolerance. Transplantation 2008; 85: 369.
23. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4: 2118.
24. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554.
25. Takaya S, Bronsther O, Iwaki Y, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400.
26. Scornik JC, Soldevilla-Pico C, Van der Werf WJ, et al. Susceptibility of liver allografts to high or low concentrations of preformed antibodies as measured by flow cytometry. Am J Transplant 2001; 1: 152.
27. Muro M, Marin L, Miras M, et al. Liver recipients harbouring antidonor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005; 14: 91.
28. Kasahara M, Kiuchi T, Takakura K, et al. Postoperative flow cytometry crossmatch in living donor liver transplantation: clinical significance of humoral immunity in acute rejection. Transplantation 1999; 67: 568.
29. Fontana M, Moradpour D, Aubert V, et al. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858.
30. O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868.
31. Paterno F, Shiller M, Tillery G, et al. Bortezomib for acute antibodymediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526.
32. Goh A, Scalamogna M, De Feo T, et al. Human leukocyte antigen crossmatch testing is important for liver retransplantation. Liver Transpl 2010; 16: 308.
33. Girnita A, Mazariegos GV, Castellaneta A, et al Liver transplant recipients weaned off immunosuppression lack circulating donorspecific antibodies. Hum Immunol 2010; 71: 274.
34. Cai J, Terasaki PI, Bloom DD, et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004; 78: 919.
35. Hourmant M, Cesbron-Gautier A, Terasaki PI, et al. Frequency and clinical implications of development of donor-specific and nondonor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol 2005; 16: 2804.
36. Mizutani K, Terasaki P, Rosen A, et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 2005; 5: 2265.
37. Cai J, Terasaki PI, Mao Q, et al. Development of nondonor-specific HLA-DR antibodies in allograft recipients is associated with shared epitopes with mismatched donor DR antigens. Am J Transplant 2006; 6: 2947.
38. Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27: 926.
39. Ohe H, Waki K, Yoshitomi M, et al. Factors affecting operational tolerance after pediatric living-donor liver transplantation: impact of early post-transplant events and HLA match. Transpl Int 2012; 25: 97.
40. Evrard V, Otte JB, Sokal E, et al. Impact of surgical and immunological parameters in pediatric liver transplantation: a multivariate analysis in 500 consecutive recipients of primary grafts. Ann Surg 2004; 239: 272.
41. Markiewski MM, DeAngelis RA, Lambris JD. Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol Immunol 2006; 43: 45.
42. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis 2009; 29: 91.
43. Devos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598.
44. Willicombe M, Brookes P, Sergeant R, et al. De novo DQ donorspecific antibodies are associated with a significant risk of antibodymediated rejection and transplant glomerulopathy. Transplantation 2012; 94: 172.
45. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500.
46. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11: 312.
47. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74: 799.
48. Regele H. Non-HLA antibodies in kidney allograft rejection: convincing concept in need of further evidence. Kidney Int 2011; 79: 583.
49. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005; 365: 1570.
50. Kaneku H, O'Leary JG, Taniguchi M, et al. Donor-specific HLA antibodies of IgG3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984.
51. Adeyi O, Alexander G, Baiocchi L, et al. Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18: 1154.
52. Waki K, Sugawara Y, Mizuta K, et al. Living-donor liver transplantation at the University of Tokyo, 1996Y2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance. Clin Transpl 2011: 223.
53. Sugawara Y, Tamura S, Kaneko J, et al. Positive lymphocytotoxic crossmatch does not adversely affect survival in living donor liver transplantation. Dig Surg 2009; 26: 482.
54. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289.